Tenaya Therapeutics Presents Preclinical Data at MDA 2026 Highlighting TN-301’s Potential to Correct Skeletal and Cardiac Muscle Decline in Duchenne Muscular Dystrophy
Rhea-AI Summary
Tenaya Therapeutics (NASDAQ: TNYA) presented preclinical data at MDA 2026 showing its selective HDAC6 inhibitor TN-301 improved muscle performance and corrected DMD cardiomyopathy drivers in vitro and in vivo. TN-301 restored mdx mouse muscle function to wild-type levels at 3 mg/kg and corrected human DMD iPSC-cardiomyocyte defects. A Phase 1 in healthy adults showed TN-301 was generally well tolerated without serious adverse events or dose-limiting toxicities. Tenaya plans to advance TN-301 toward Phase 2 clinical development, with HFpEF and DMD among prioritized indications.
Positive
- Restored muscle function to wild-type levels in mdx mice at 3 mg/kg within five weeks
- Corrected cardiomyocyte defects in human DMD iPSC-derived cardiomyocytes (calcium and mitochondrial function)
- Phase 1 tolerability signal: no serious adverse events or dose-limiting toxicities reported in healthy adults
Negative
- Data are preclinical: efficacy shown in animal and cellular models, not yet demonstrated in DMD patients
- Comparative claim versus givinostat is based on nonclinical models and may not predict clinical outcomes
News Market Reaction – TNYA
On the day this news was published, TNYA gained 7.84%, reflecting a notable positive market reaction. Argus tracked a peak move of +5.7% during that session. Argus tracked a trough of -13.7% from its starting point during tracking. Our momentum scanner triggered 18 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $16M to the company's valuation, bringing the market cap to $224M at that time. Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
TNYA is up 8.39% with strong volume, while only one momentum peer (TRDA) is also up (2.94%) and other close peers show mixed moves. This points to a stock-specific reaction to the TN-301 preclinical update rather than a broad sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Mar 05 | Strategic partnership | Positive | +40.9% | Major Alnylam collaboration with up to 15 targets and milestone potential. |
| Mar 02 | Conference participation | Neutral | -3.5% | Announcement of Leerink healthcare conference fireside chat and webcast details. |
| Jan 09 | Strategic update | Positive | -1.0% | 2026 priorities, clinical milestones and funding runway outlined with recent capital raise. |
| Dec 12 | Equity offering priced | Negative | -37.5% | Public offering of 50,000,000 units at $1.20 with five-year warrants. |
| Dec 11 | Equity offering proposed | Negative | -37.5% | Proposed unit offering of common stock, pre-funded warrants and warrants under Form S-3. |
Positive, non-dilutive catalysts such as the Mar 5 2026 Alnylam collaboration coincided with a strong gain of +40.92%, while equity offerings on Dec 11–12 2025 saw sharp declines of -37.5%. Conference and strategy updates have produced smaller, mixed reactions.
Over the past six months, Tenaya announced dilutive offerings in Dec 2025 that led to -37.5% moves on both the proposed and priced deals. In Jan 2026, the company outlined 2026 priorities and funding visibility through mid-2027 with only a modest share reaction. A Leerink conference appearance on Mar 2 2026 saw a slight decline, while the major Alnylam collaboration on Mar 5 2026 drove a strong +40.92% move, highlighting market sensitivity to large strategic partnerships. Today’s TN-301 preclinical data add to that momentum around the pipeline.
Market Pulse Summary
The stock moved +7.8% in the session following this news. A strong positive reaction aligns with TNYA’s history of responding well to major pipeline and partnership updates, as seen with the +40.92% move on the Alnylam deal. Today’s TN-301 preclinical data, showing functional restoration in DMD models, come against a backdrop of heavy insider selling but also a 11.51% short interest and 6.15 days to cover, which could amplify volatility if sentiment shifts quickly.
Key Terms
hdac6 inhibitor medical
pan hdac inhibitor medical
duchenne muscular dystrophy medical
cardiomyopathy medical
induced pluripotent stem cells medical
qt prolongation medical
autophagy medical
creatine kinase medical
AI-generated analysis. Not financial advice.
Tenaya’s Highly Selective HDAC6 Inhibitor TN-301 Outperformed Approved Pan-HDAC Inhibitor Givinostat in Improving Muscle Function and Correcting Drivers of DMD Cardiomyopathy
New Data Confirm TN-301’s Differentiated Mechanism and Opportunities to Positively Address Rare and Prevalent Cardiac, Metabolic and Muscular Conditions
Tenaya Plans to Advance TN-301 Toward Phase 2 Clinical Development
ORLANDO, Fla. and SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today presented encouraging preclinical data evaluating TN-301, the company’s highly selective HDAC6 inhibitor, at the Muscular Dystrophy Association’s Clinical & Scientific Conference 2026 (MDA 2026). In in vitro and in vivo models of Duchenne muscular dystrophy (DMD), TN-301 improved muscle performance and corrected key drivers of DMD cardiomyopathy.
TN-301 is Tenaya’s potent and highly selective small molecule HDAC6 inhibitor with a multi-modal mechanism of action, including reducing inflammation, metabolic and mitochondrial dysregulation and fibrosis, and improving autophagy, which may have potential benefit in rare or prevalent cardiac, metabolic, muscle and pulmonary diseases. In a Phase 1 safety study in healthy adults, TN-301 was generally well tolerated over a wide dose range and did not demonstrate serious adverse events or dose-limiting toxicities. Based on this profile, Tenaya has identified several potential indications of interest, supported by the company’s previously published preclinical results in heart failure with preserved ejection fraction (HFpEF) and genetic dilated cardiomyopathy.
Today’s presentation at MDA 2026 adds to this body of research, highlighting TN-301’s potential in DMD cardiomyopathy and muscle degeneration. Tenaya plans to advance TN-301 toward clinical studies in patients, with HFpEF and DMD being among the most promising potential indications identified to date.
“DMD-related cardiomyopathy is the most common cause of death among individuals with DMD, and despite advances in care, there is a profound unmet need for treatments that can address both skeletal muscle atrophy and cardiac decline,” said Kathy Ivey, Ph.D., Senior Vice President, Research of Tenaya Therapeutics. “Recognizing that many of the drivers of DMD-related cardiomyopathy and skeletal muscle degeneration corresponded to TN-301’s multi-modal mechanism of action, we conducted a series of studies and found that TN-301 outperformed the approved agent, givinostat, achieving functional improvements in mdx mice that restored muscle performance to wild-type levels while also correcting key DMD-associated cardiomyocyte defects.”
The pan HDAC inhibitor, givinostat, is approved in the U.S. and EU for the treatment of DMD and has been shown to slow skeletal muscle decline in DMD patients as demonstrated clinically by the 4 Stair Climb (4SC) and North Star Ambulatory Assessment (NSAA). However, its use is limited by side effects including thrombocytopenia, and by QT prolongation risk – liabilities not observed clinically in the Phase 1 study of TN-301. To test the hypothesis that TN-301 may delay or reverse both skeletal muscle pathology and cardiomyopathy in DMD, Tenaya researchers conducted studies comparing TN-301 with givinostat. Key findings presented at MDA 2026 include:
- TN-301 treatment at doses as low as 3 mg/kg improved grip strength to wild-type levels within five weeks, whereas mdx mice treated with givinostat (10 mg/kg, approximating clinical exposures) failed to reach wild-type performance.
- TN-301-mediated functional improvements were accompanied by reductions in circulating creatine kinase activity and favorable changes in gene expression, indicating reduced muscle cell injury.
- In cardiomyocytes derived from human DMD induced pluripotent stem cells, TN-301 corrected calcium handling abnormalities and mitochondrial dysfunction, while givinostat exacerbated these established drivers of DMD cardiomyopathy.
These positive preclinical data – as well as data from others using HDAC6 inhibitors in DMD disease models – collectively suggest that HDAC6 inhibition may be substantially driving the benefits observed to date with pan-HDAC inhibitors in DMD clinical studies.
These results were presented at MDA 2026 by Dr. Ivey in a poster presentation, titled “TN-301, Tenaya’s HDAC6 Inhibitor, Improves Muscle Function and Molecular Pathology in mdx Mice and Corrects Human DMD iPSC-Cardiomyocyte Phenotypes”.
About TN-301
TN-301 is Tenaya’s highly specific small molecule histone deacetylase (HDAC) 6 inhibitor, which has demonstrated promising preclinical potential for the treatment of heart failure with preserved ejection fraction (HFpEF) and Duchenne muscular dystrophy (DMD). In a Phase 1 clinical trial of healthy volunteers, TN-301 was generally well tolerated across the broad range of doses studied, with dose-responsive pharmacokinetics and a half-life supportive of once-daily dosing. Notably, there were no changes in histone acetylation with TN-301, underscoring the >3000-fold selectivity of TN-301 for HDAC6 over other HDACs and supporting the potential to avoid the off-target effects observed with less selective HDAC6 or pan-HDAC inhibition.
HDAC6 inhibition exerts its benefits on the heart and other organs in the body by modifying cytoskeletal and other proteins to coordinate cellular processes through a multi-modal mechanism of action. In preclinical studies, Tenaya’s HDAC6 inhibitors have been shown to reduce inflammation, oxidative stress, fibrosis, and metabolic dysregulation, as well as improve autophagy, protein quality control, mitochondrial metabolism, and lipid metabolism. Tenaya is committed to exploring opportunities to advance TN-301 into clinical studies of patients with cardiac, metabolic, muscular or pulmonary disorders where there is strong alignment between the activity of HDAC6 inhibition and the pathophysiology of disease.
About Tenaya Therapeutics
Tenaya Therapeutics is a clinical-stage biotechnology company committed to a bold mission: to discover, develop and deliver potentially curative therapies that address the underlying drivers of heart disease. Tenaya’s pipeline includes clinical-stage candidates TN-201, a gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and TN-401, a gene therapy for PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). Tenaya has employed a suite of integrated internal capabilities, including modality agnostic target validation, capsid engineering and manufacturing, to generate a portfolio of novel medicines based on genetic insights, including TN-301, a clinical-stage small molecule HDAC6 inhibitor for the potential treatment of heart failure and related cardio/muscular disease, and multiple early-stage programs in preclinical development aimed at the treatment of both rare genetic disorders and more prevalent heart conditions. For more information, visit www.tenayatherapeutics.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “opportunities,” “plans,” “may,” “potential,” “promising,” “committed,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, the clinical, therapeutic and commercial potential of TN-301 as a treatment for HFpEF, DMD and other cardiac, metabolic, muscle and pulmonary diseases and Tenaya’s commitment to exploring opportunities to advance TN-301 into clinical studies in such indications. The forward-looking statements contained herein are based upon Tenaya’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: the potential failure of TN-301 to demonstrate safety and/or efficacy in clinical testing; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating TN-301; the timing, scope and likelihood of regulatory filings and approvals for TN-301; risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics and operating as an early stage company; Tenaya’s ability to develop, initiate or complete preclinical studies and clinical trials, and obtain approvals, for TN-301 or any of its product candidates; Tenaya’s continuing compliance with applicable legal and regulatory requirements; Tenaya’s ability to raise any additional funding it will need to continue to pursue its business and product development plans; Tenaya’s reliance on third parties; Tenaya’s manufacturing, commercialization and marketing capabilities and strategy; the loss of key scientific or management personnel; competition in the industry in which Tenaya operates; Tenaya’s ability to obtain and maintain intellectual property protection for its product candidates; general economic and market conditions; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Tenaya files from time to time with the Securities and Exchange Commission. These forward-looking statements are made as of the date of this press release, and Tenaya assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Tenaya Contacts
Michelle Corral
VP, Corporate Communications and Investor Relations
IR@tenayathera.com
Investors
Anne-Marie Fields
Precision AQ
annemarie.fields@precisionaq.com
Media
Wendy Ryan
Ten Bridge Communications
wendy@tenbridgecommunications.com
FAQ
What did Tenaya announce about TN-301 at MDA 2026 for DMD (TNYA)?
How did TN-301 compare with givinostat in Tenaya's MDA 2026 data for TNYA?
What safety information did Tenaya report for TN-301 from Phase 1 (TNYA)?
What are Tenaya's next development plans for TN-301 and which indications (TNYA)?
What specific preclinical efficacy metrics did Tenaya present for TN-301 in DMD (TNYA)?
